Profile data is unavailable for this security.
About the company
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
- Revenue in EUR (TTM)1.11bn
- Net income in EUR56.58m
- Incorporated2017
- Employees3.50k
- LocationDermapharm Holding SELil-Dagover-Ring 7GRUENWALD 82031GermanyDEU
- Phone+49 89641860
- Fax+49 8 964186130
- Websitehttps://ir.dermapharm.de/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd | 143.14m | 17.84m | 1.90bn | 947.00 | 106.75 | 24.22 | 97.70 | 13.31 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
| China Medical System Holdings Ltd | 1.02bn | 304.69m | 1.93bn | 5.70k | 6.37 | 0.985 | 5.82 | 1.90 | 1.05 | 1.05 | 3.51 | 6.80 | 0.4517 | 3.42 | 6.19 | 1,510,450.00 | 13.44 | 18.44 | 15.70 | 21.14 | 76.24 | 75.47 | 29.76 | 34.26 | 3.98 | -- | 0.0772 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| Concord Biotech Ltd | 112.36m | 34.04m | 1.95bn | 1.38k | 57.19 | 11.54 | 48.70 | 17.32 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 149.96m | 26.44m | 1.99bn | 1.55k | 74.53 | 6.90 | -- | 13.25 | 0.9769 | 0.9769 | 5.54 | 10.55 | 0.3743 | 1.21 | 4.71 | 764,598.40 | 6.69 | 5.86 | 9.15 | 7.59 | 63.15 | 55.41 | 17.87 | 17.20 | 1.08 | 33.77 | 0.3356 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Almirall SA | 909.92m | -38.77m | 1.99bn | 1.90k | -- | 1.32 | -- | 2.19 | -0.1797 | -0.1797 | 4.28 | 7.05 | 0.4107 | 1.51 | 6.15 | 477,897.10 | -1.75 | 0.922 | -1.97 | 1.08 | 75.56 | 78.06 | -4.26 | 2.48 | 1.94 | 12.34 | 0.1927 | -- | 3.62 | 3.40 | -998.72 | -- | -23.27 | -- |
| Grand Pharmaceutical Group Ltd | 1.24bn | 222.02m | 1.99bn | 10.53k | 8.87 | 1.10 | 7.37 | 1.60 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Dermapharm Holding SE | 1.11bn | 56.58m | 2.00bn | 3.50k | 35.33 | 3.43 | 12.19 | 1.79 | 1.05 | 1.05 | 20.69 | 10.81 | 0.5137 | 1.25 | 9.68 | 318,823.00 | 2.51 | 8.68 | 3.01 | 10.06 | 63.32 | 61.94 | 4.89 | 12.31 | 0.7517 | 2.70 | 0.6367 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
| Chongqing Taiji Industry Group Co Ltd | 1.96bn | 105.87m | 2.01bn | 12.59k | 18.95 | 4.08 | -- | 1.03 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| BrightGene Bio-Medical Technology Co Ltd | 154.20m | 24.85m | 2.02bn | 1.16k | 82.30 | 6.54 | -- | 13.08 | 0.4569 | 0.4569 | 2.87 | 5.75 | 0.2463 | 1.69 | 4.43 | 1,051,700.00 | 3.43 | 6.53 | 4.29 | 7.93 | 54.92 | 56.93 | 13.93 | 19.90 | 1.45 | 4.86 | 0.4787 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
| Tonghua Dongbao Pharmaceutical Co Ltd | 381.02m | 143.71m | 2.07bn | 3.20k | 14.48 | 2.21 | -- | 5.43 | 0.5682 | 0.5682 | 1.51 | 3.73 | 0.403 | 0.8622 | 4.57 | 939,125.30 | 15.20 | 18.68 | 15.84 | 19.68 | 79.89 | 78.73 | 37.71 | 39.20 | 5.04 | -- | 0.03 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
Data as of Jul 05 2024. Currency figures normalised to Dermapharm Holding SE's reporting currency: Euro EUR
10.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mawer Investment Management Ltd.as of 29 Jun 2023 | 1.62m | 3.00% |
| Grandeur Peak Global Advisors LLCas of 31 Jan 2024 | 812.28k | 1.51% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 635.45k | 1.18% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 610.87k | 1.14% |
| Janus Henderson Investors UK Ltd.as of 31 Mar 2024 | 541.72k | 1.01% |
| Danske Bank A/S (Investment Management)as of 31 May 2024 | 402.38k | 0.75% |
| Amundi Asset Management SA (Investment Management)as of 05 Jun 2024 | 374.86k | 0.70% |
| Lupus alpha Asset Management AGas of 31 Dec 2023 | 337.00k | 0.63% |
| DNCA Finance SAas of 29 Dec 2023 | 276.47k | 0.51% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 263.54k | 0.49% |
More ▼
Data from 31 Dec 2023 - 26 Jun 2024Source: FactSet Research Systems Inc.
